Fibrates and future PPARα agonists in the treatment of cardiovascular disease

Nature Clinical Practice Cardiovascular Medicine

Volumn 5, Issue 9, 2008, Pages 542-553

  Staels, Bart ^a   Maes, Michel ^b   Zambon, Alberto ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

^b University of Padova ^*

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CIPROFIBRATE; CLOFIBRATE; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLYCOSYLATED HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PLACEBO; PRAVASTATIN; SIMVASTATIN; ANTILIPEMIC AGENT; CARDIOVASCULAR AGENT; CLOFIBRIC ACID;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RESPONSE; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; METABOLIC SYNDROME X; MONOTHERAPY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; ANIMAL; BLOOD; DRUG COMBINATION; DRUG POTENTIATION; METABOLISM; RISK ASSESSMENT; TREATMENT OUTCOME;

ANIMALS; ANTILIPEMIC AGENTS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; CLOFIBRIC ACID; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPIDS; PPAR ALPHA; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 50649089597     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1278     Document Type: Review

References (82)

1. LaRosa JC (2005) At the heart of statin benefit. J Am Coll Cardiol 46: 1863
2. Superko HR (1996) Beyond LDL cholesterol reduction. Circulation 94: 2351-2354
3. Cannon CP et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 1495-1504
4. Cordain L et al. (2002) The paradoxical nature of hunter-gatherer diets: Meat based, yet non-atherogenic. Eur J Clin Nutr 56 (Suppl 1): S42-S52
5. O'Keefe JH and Cordain L (2004) Cardiovascular disease resulting from a diet and lifestyle at odds with our Paleolithic genome: How to become a 21st century hunter-gatherer. Mayo Clin Proc 70: 101-108
6. Libby P (2005) The forgotten majority: Unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 46: 1225-1228
7. Bruckert E et al. (2005) Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther 19: 403-414
8. Alsheikh-Ali AA et al. (2007) Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer. J Am Coll Cardiol 50: 409-418
9. Violi F et al.; MRC/BHF Heart Protection Study (2002) MRC/BHF Heart Protection Study. Lancet 360: 7-22
10. Colhoun HM et al.; CARDS Investigators (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 364: 685-696
11. Sever PS et al. (2005) Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial - lipid-lowering arm (ASCOT-LLA). Diabetes Care 28: 1151-1157
12. Wanner C et al.; Deutsche Diabetes-Dialyse-Studie (4D) Study Group (2004) Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): Demographic and baseline characteristics. Kidney Blood Press Res 27: 259-266
13. Knopp RH et al. (2006) Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29: 1478-1485
14. Costa J et al. (2006) Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: Meta-analysis of randomised controlled trials. BMJ 332: 1115-1124
15. Stratton IM et al. (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321: 405-412
16. Hokanson JE and Austin MA (1996) Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 3: 213-219
17. Bansal S et al. (2007) Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298: 309-316
18. McBride PE (2007) Triglycerides and risk for coronary heart disease. JAMA 298: 336-338
19. Jacobson TA et al. (2007) Hypertriglyceridemia and cardiovascular risk reduction. Clin Ther 29: 763-777
20. Miller M et al.; for the PROVE IT-TIMI 22 Investigators (2008) Impact of triglyceride levels beyond low density lipoprotein cholesterol after an acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 51: 724-730
21. Ballantyne CM et al. (1999) Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 99: 736-443
22. Mackness MI et al. (1993) The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 294: 829-834
23. Cockerill GW et al. (1995) High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 15: 1987-1994
24. Kontush A and Chapman MJ (2006) Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 3: 144-153
25. Lamarche B et al. (1999) HDL metabolism in hypertriglyceridemic states: An overview. Clin Chim Acta 286: 145-161
26. Birjmohun RS et al. (2005) Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials. J Am Coll Cardiol 45: 185-197
27. Robins SJ et al. (2001) Relation of gemfibrozil treatment and liAid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285: 1585-1591
28. Lefebvre et al. (2006) Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 116 571-680
29. Grundy SM et al. (2005) Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 95: 462-468
30. Staels B et al. (1998) Mechanisms of action fibrates on lipid and lipoprotein metabolism. Circulation 98: 2088-2093
31. Seiler C et al. (1995) Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. J Am Coll Cardiol 26: 1615-1622
32. Koh KK et al. (2005) Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 28: 1419-1424
33. Playford DA et al. (2003) Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. Atherosclerosis 168: 169-179
34. Evans M et al. (2000) Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 101: 1773-1779
35. Wilmink HW et al. (2001) Effect of statin versus fibrate on postprandial endothelial dysfunction: Role of remnant-like particles. Cardiovasc Res 50: 577-582
36. Andrews TC et al. (1997) Effect of gemfibrozil +/- niacin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <60 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl. Am J Cardiol 80: 831-835
37. Ogata T et al. (2004) Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol 43: 1481-1488
38. Han SH et al. (2005) Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. Hypertension 46: 1086-1092
39. Zambon A et al. (2006) Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: Clinical and experimental evidence. Arterioscler Thromb Vasc Biol 26: 977-986
40. Koh et al. (2005) Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 45: 1649-1653
41. Aguilar-Salinas CA et al. (2001) Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: An open-label, multicenter study. Metabolism 50: 729-733
42. 2 mediated activation of transforming growth factor beta in human mesangial cells. Antiox Redox Signal 4: 877-884
43. Park CW et al. (2006) PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 69: 1511-1517
44. Chen LL et al. (2006) Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1. Vascul Pharmacol 44: 309-315
45. Park CW et al. (2006) Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha. Diabetes 55: 885-893
46. Kamijo Y et al. (2002) Identification of functions of peroxisome proliferator-activated receptor alpha in proximal tubules. J Am Soc Nephrol 13: 16591-1702
47. Sato M (2005) Peroxisome proliferator activated receptor ligands and angiogenesis. Nippon Rinsho 63: 603-608
48. Panigrahy D et al. (2008) PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci USA 105: 985-990
49. Ruotolo G et al. (2000) Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: Beneficial effects of bszafibrate treatment. J Am Coll Cardiol 35: 647-654
50. Wilkinson-Berka JL et al. (2006) The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy. Curr Med Chem 13: 3307-3317
51. Blann AD et al. (2001) Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol 15: 1160-1163
52. Kim J et al. (2007) Fenofibrate regulates endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res 84: 886-893
53. Harrold BP et al. (1969) A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes 18: 285-291
54. Dorne PA (1977) Exudative diabetic retinopathy. The use of clofibrate in the treatment of hard exudates using a reduced but prolonged dosage over several years. Arch Ophtalmol 37: 393-400
55. Frick MH et al. (1907) Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 96: 2137-2143
56. Ericsson CG et al. (1996) Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347: 849-853
57. DAIS investigators (2001) Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357: 905-910
58. Rubins HE et al. (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341: 410-418
59. Robins SJ et al. (2001) Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: A randomized controlled trial. JAMA 285: 1585-1591
60. Bloomfield-Rubins H et al. (2002) Diabetes, plasma insulin and cardiovascular disease: Subgroup analysis. from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 162: 2597-2604
61. Frick MH et al. (1987) Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317: 1237-1245
62. Tenkanen L et al. (1995) Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: Experience from the Helsinki Heart Study. Circulation 92: 1779-1785
63. The Bezafibrate Infarction Prevention study Group (2000) Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study. Circulation 102: 21-27
64. Goldenberg J et al. (2008) Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: An extended follow-up of the BIP trial. J Am Coll Cardiol 51: 459-465
65. Tenenbaum A et al. (2005) Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 165: 1154-1160
66. Keech A et al.; FIELD study investigators (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9,795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 366: 1849-1861
67. Scott R et al.; on behalf of the FIELD Investigators (2007) Features of metabolic syndrome identify individuals with type 2 diabetes mellitus at high risk for cardiovascular events and greater absolute benefits of fenofibrate [abstract]. Circulation 116: II_838
68. Keech A et al.; FIELD study investigators (2007) Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet 370: 1687-1697
69. Hiukka A et al. (2007) Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. Diabetologia 50: 2067-2075
70. Grundy SM et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227-239
71. Athyros VG et al. (2002) Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hypedipidemia. Diabetes Care 25: 1198-1202
72. Watts GF (2003) Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 52: 803-811
73. Farnier M et al. (2007) Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J 153: 335-338
74. Hottelart C et al. (1999) Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency. Nephrologie 20: 41-44
75. Luc G et al. (2004) Fenofibrate increases homocysteinemia through a PPARα-mediated mechanism. J Cardiovasc Pharmacol 43 452-453
76. Genest J et al. (2004) Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. Am J Cardiol 93: 848-853
77. Davidson MH et al. (2006) Statin/fibrate combination in patients with metabolic syndrome or diabetes: Evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf 5: 145-156
78. Davidson MH et al. (2007) Safety considerations with fibrate therapy. Am J Cardiol 99 (Suppl): 3C-18C
79. Prueksaritanont T et al. (2002) Effect of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 30: 1280-1287
80. Pourcet B et al. (2006) Selective PPAR modulators, dual and pan PPAR agonists: Multimodal drugs for the treatment of type 2 diabetes and atherosclerosis. Expert Opin Emerg Drugs 111: 379-401
81. Duez H et al. (2005) Regulation of human apo A-I by gemfibrozil and fenofibrate through selective PPAR-α modulation. Arteriosder Thromb Vasc Biol 25: 585-591
82. ACCORD Study Group; Buse JB et al. (2007) Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: Design and methods. Am J Cardiol 99 (Suppl): 21i-33i